500 rub
Journal Technologies of Living Systems №2 for 2026 г.
Article in number:
Podoplanin as a modern tumor marker: A literature review
Type of article: overview article
DOI: https://doi.org/10.18127/j20700997-202602-01
UDC: 616-006-074:577.112:578.52(048.8)
Keywords: Podoplanin tumor marker oncological diseases diagnostics prognosis
Authors:

I.A. Krupatkin1, A.V. Kolpashchikov2, A.V. Zaborovsky3, N.E. Kushlinskii4

1–4 Russian University of Medicine of the Ministry of Health of the Russia (Moscow, Russia)

4 N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia (Moscow, Russia)

1 krupatkin.sci@gmail.com, 2 kolpaschikov@mail.ru, 3 azabor@mail.ru, 4 kne3108@gmail.com

Abstract:

Current research suggests a link between podoplanin and carcinogenesis. Increased podoplanin expression has been identified in various malignant tumors and, in most cases, is associated with increased malignancy. However, its role in the diagnosis and prognosis of a number of oncological diseases remains controversial, attracting the interest of many researchers in discussing this issue. This work is to analyze the significance of podoplanin in the diagnosis and prognosis of oncological diseases. Podoplanin is a transmembrane protein that regulates normal physiological processes such as lymph vessel formation, coagulation, and immune response. However, in oncological diseases, its role becomes negative: increased expression of podoplanin promotes aggressive tumor growth, invasion and metastasis. It stimulates the motility of cancer cells, participates in the formation of metastases through platelet activation, and supports the work of special cell populations that form the tumor microenvironment. Due to this, podoplanin is an important diagnostic and prognostic marker – according to current research, the level of its soluble form in the blood is associated with the degree of malignancy, metastasis, risk of associated coagulopathies and survival prognosis. Podoplanin is an important biological regulator, a promising target for the diagnosis and treatment of oncological diseases, which makes it an object of study both in modern oncology and in medical science in general.

Pages: 5-25
For citation

Krupatkin I.A., Kolpashchikov A.V., Zaborovsky A.V., Kushlinskii N.E. Podoplanin as a modern tumor marker: A literature review. Technologies of Living Systems. 2026. V. 23. № 2. Р. 5-25. DOI: https://doi.org/10.18127/j20700997-202602-01 (In Russian).

References
  1. Quintanilla M., Montero-Montero L., Renart J., Martín-Villar E. Podoplanin in Inflammation and Cancer. Int J Mol Sci. 2019. Feb 6.
    V. 20(3). P. 707. DOI: 10.3390/ijms20030707
  2. Renart J., San Mauro D., Agorreta A. et al. Evolutionary history of the podoplanin gene. Gene Rep. 2018. V. 13. P. 28–37. DOI: 10.1016/j.genrep.2018.08.005
  3. Toyoshima M., Nakajima M., Yamori T., Tsuruo T. Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26. Cancer Res. 1995 Feb 15. V. 55(4). P. 767–773.
  4. Kato Y., Fujita N., Kunita A. et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J. Biol. Chem. 2003 Dec 19. V. 278(51). P. 51599-51605. DOI: 10.1074/jbc.M309935200
  5. Takemoto A., Miyata K., Fujita N. Platelet-activating factor podoplanin: from discovery to drug development. Cancer Metastasis Rev. 2017 Jun. V. 36(2). P. 225-234. DOI: 10.1007/s10555-017-9672-2
  6. Cheok Y.Y., Tan G.M.Y., Chan Y.T. et al. Podoplanin and its multifaceted roles in mammalian developmental program. Cells Dev. 2024 Dec. V. 180. P. 203943. DOI: 10.1016/j.cdev.2024.203943
  7. Ozaki Y., Tamura S., Suzuki-Inoue K. New horizon in platelet function: with special reference to a recently-found molecule, CLEC-2. Thromb. J. 2016 Oct 4. V. 14(Suppl 1). P. 27. DOI: 10.1186/s12959-016-0099-8
  8. Tal O., Lim H.Y., Gurevich I. et al. DC mobilization from the skin requires docking to immobilized CCL21 on lymphatic endothelium and intralymphatic crawling. J. Exp. Med. 2011 Sep 26. V. 208(10). P. 2141-2153. DOI: 10.1084/jem.20102392
  9. Fuertbauer E., Zaujec J., Uhrin P. et al. Thymic medullar conduits-associated podoplanin promotes natural regulatory T cells. Immunol. Lett. 2013 Jul-Aug. V. 154(1-2). P. 31-41. DOI: 10.1016/j.imlet.2013.07.007
  10. Cueni L.N., Detmar M. Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. Exp. Cell Res. 2009 Jun 10. V. 315(10). P. 1715-1723. DOI: 10.1016/j.yexcr.2009.02.021
  11. Tsuneki M., Maruyama S., Yamazaki M. et al. Extracellular heat shock protein A9 is a novel interaction partner of podoplanin in oral squamous cell carcinoma cells. Biochem. Biophys. Res. Commun. 2013 Apr 26. V. 434(1). P. 124-130. DOI: 10.1016/j.bbrc.2013.03.057
  12. Nakazawa Y., Sato S., Naito M. et al. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood. 2008 Sep 1. V. 112(5). P. 1730-1739. DOI: 10.1182/blood-2007-11-124693
  13. Martín-Villar E., Fernández-Muñoz B., Parsons M. et al. Podoplanin associates with CD44 to promote directional cell migration. Mol. Biol. Cell. 2010 Dec. V. 21(24). P. 4387-4399. DOI: 10.1091/mbc.E10-06-0489
  14. Martín-Villar E., Megías D., Castel S. et al. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J. Cell Sci. 2006 Nov 1. V. 119(Pt 21). P. 4541-4553. DOI: 10.1242/jcs.03218
  15. Li Y.Y., Zhou C.X., Gao Y. Podoplanin promotes the invasion of oral squamous cell carcinoma in coordination with MT1-MMP and Rho GTPases. Am. J. Cancer Res. 2015 Jan 15. V. 5(2). P. 514-529. Erratum in: Am. J. Cancer Res. 2022 Mar 15. V. 12(3). P. 1433-1434.
  16. Martín-Villar E., Scholl F.G., Gamallo C. et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int. J. Cancer. 2005 Mar 1. V. 113(6). P. 899-910. DOI: 10.1002/ijc.20656
  17. Sekiguchi T., Takemoto A., Takagi S. et al. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget. 2016 Jan 26. V. 7(4). P. 3934-3946. DOI: 10.18632/oncotarget.6598
  18. Troncoso M.F., Ferragut F., Bacigalupo M.L. et al. Galectin-8: a matricellular lectin with key roles in angiogenesis. Glycobiology. 2014 Oct. V. 24(10). P. 907-914. DOI: 10.1093/glycob/cwu054
  19. Kerjaschki D., Regele H.M., Moosberger I. et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J. Am. Soc. Nephrol. 2004 Mar. V. 15(3). P. 603-612. DOI: 10.1097/01.asn.0000113316.52371.2e
  20. Tsuneki M., Maruyama S., Yamazaki M. et al. Extracellular heat shock protein A9 is a novel interaction partner of podoplanin in oral squamous cell carcinoma cells. Biochem. Biophys. Res. Commun. 2013 Apr 26. V. 434(1). P. 124-130. DOI: 10.1016/j.bbrc.2013.03.057
  21. Sheng M., Sun R., Fu J., Lu G. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis. BMC Cancer. 2024 Apr 1;24(1):399. DOI: 10.1186/s12885-024-12194-w. PMID: 38561690; PMCID: PMC10983743.
  22. Suzuki-Inoue K., Inoue O., Ding G. et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J. Biol. Chem. 2010 Aug 6. V. 285(32). P. 24494-24507. DOI: 10.1074/jbc.M110.130575
  23. Uhrin P., Zaujec J., Breuss J.M. et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood. 2010 May 13. V. 115(19). P. 3997–4005. DOI: 10.1182/blood-2009-04-216069
  24. Hess P.R., Rawnsley D.R., Jakus Z. et al. Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. J. Clin. Invest. 2014. V. 124(01). P. 273–284.
  25. Lowe K.L., Finney B.A., Deppermann C. et al. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood. 2015. V. 125(24). P. 3769–3777.
  26. Boulaftali Y., Hess P.R., Getz T.M. et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J. Clin. Invest. 2013.
    V. 123(02). P. 908–916.
  27. Gros A., Syvannarath V., Lamrani L. et al. Single platelets seal neutrophil-induced vascular breaches via GPVI during immunecomplex-mediated inflammation in mice. Blood. 2015. V. 126(08). P. 1017–1026.
  28. Asai J., Hirakawa S., Sakabe J. et al. Platelets regulate the migration of keratinocytes via podoplanin/CLEC-2 signaling during cutaneous wound healing in mice. Am. J. Pathol. 2016. V. 186(01). P. 101–108.
  29. Meyer J., Lejmi E., Fontana P. et al. A focus on the role of platelets in liver regeneration: do plateletendothelial cell interactions initiate the regenerative process? J. Hepatol. 2015. V. 63(05). P. 1263–1271.
  30. Kono H., Fujii H., Suzuki-Inoue K. et al. The platelet-activating receptor C-type lectin receptor-2 plays an essential role in liver regeneration after partial hepatectomy in mice. J. Thromb. Haemost. 2017. V. 15(05). P. 998–1008.
  31. Van Raemdonck K., Umar S., Shahrara S. The pathogenic importance of CCL21 and CCR7 in rheumatoid arthritis. Cytokine Growth Factor Rev. 2020 Oct. V. 55. P. 86-93. DOI: 10.1016/j.cytogfr.2020.05.007
  32. Han L., Zhang L. CCL21/CCR7 axis as a therapeutic target for autoimmune diseases. Int. Immunopharmacol. 2023 Aug. V. 121. P. 110431. DOI: 10.1016/j.intimp.2023.110431
  33. Chen W.S., Cao Z., Sugaya S. et al. Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3. Nat. Commun. 2016 Apr 12. V. 7. P. 11302. DOI: 10.1038/ncomms11302
  34. Shi J., Chen Y., Zhao W. et al. Galectin-8 involves in arthritic condylar bone loss via podoplanin/AKT/ERK axis-mediated inflammatory lymphangiogenesis. Osteoarthritis Cartilage. 2023 Jun. V. 31(6). P. 753-765. DOI: 10.1016/j.joca.2023.01.008
  35. Bieniasz-Krzywiec P., Mazzone M. PoEMs edit breast cancer outcome. Aging (Albany NY). 2020 Feb 26. V. 12(5). P. 4045-4047. DOI: 10.18632/aging.102870
  36. Erovic B.M., Neuchrist C., Kandutsch S. et al. CD9 expression on lymphatic vessels in head and neck mucosa. Mod. Pathol. 2003 Oct. V. 16(10). P. 1028-1034. DOI: 10.1097/01.MP.0000089777.58000.B2
  37. Yáñez-Mó M., Barreiro O., Gordon-Alonso M. et al. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 2009 Sep. V. 19(9). P. 434-446. DOI: 10.1016/j.tcb.2009.06.004
  38. de Winde C.M., Makris S., Millward L.J. et al. Fibroblastic reticular cell response to dendritic cells requires coordinated activity of podoplanin, CD44 and CD9. J. Cell Sci. 2021 Jul 15. V. 134(14). P. jcs258610. DOI: 10.1242/jcs.258610
  39. Sikorska J., Gaweł D., Domek H. et al. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases. BMC Cancer. 2019 Jan 17. V. 19(1). P. 85. DOI: 10.1186/s12885-018-5239-z
  40. Tanaka K., Tanaka M., Watanabe N. et al. C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes. Sci. Rep. 2022 Dec 26. V. 12(1). P. 22356. DOI: 10.1038/s41598-022-26456-9
  41. Khalili-Tanha G., Radisky E.S., Radisky D.C., Shoari A. Matrix metalloproteinase-driven epithelial-mesenchymal transition: implications in health and disease. J. Transl. Med. 2025 Apr 11. V. 23(1). P. 436. DOI: 10.1186/s12967-025-06447-w
  42. Mishima K., Kato Y., Kaneko M.K. et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006 May. V. 111(5). P. 483-488. DOI: 10.1007/s00401-006-0063-y
  43. Mishima K., Kato Y., Kaneko M.K. et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. 2006 Jun. V. 111(6). P. 563-568. DOI: 10.1007/s00401-006-0033-4
  44. Abe S., Morita Y., Kaneko M.K. et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J. Immunol. 2013 Jun 15. V. 190(12). P. 6239-6249. DOI: 10.4049/jimmunol.1300448
  45. Chang M.C., Vargas S.O., Hornick J.L. et al. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. Int. J. Gynecol. Pathol. 2009 Jul. V. 28(4). P. 347-355. DOI: 10.1097/PGP.0b013e318195da86
  46. Takagi S., Oh-hara T., Sato S. et al. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Int. J. Cancer. 2014 Jun 1. V. 134(11). P. 2605-2614. DOI: 10.1002/ijc.28602
  47. Kato Y., Sasagawa I., Kaneko M. et al. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene. 2004 Nov 4. V. 23(52). P. 8552-8556. DOI: 10.1038/sj.onc.1207869
  48. Ariizumi T., Ogose A., Kawashima H. et al. Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors. Pathol. Int. 2010 Mar. V. 60(3). P. 193-202. DOI: 10.1111/j.1440-1827.2009.02510.x
  49. Suzuki H., Kaneko M.K., Kato Y. Roles of Podoplanin in Malignant Progression of Tumor. Cells. 2022 Feb 7. V. 11(3). P. 575. DOI: 10.3390/cells11030575
  50. Wang X., Wang X., Carvalho V. et al. Prognostic Value of Podoplanin in Various Tumors. Technol. Cancer Res. Treat. 2021 Jan-Dec.
    V. 20. P. 15330338211038142. DOI: 10.1177/15330338211038142
  51. Sankiewicz A., Guszcz T., Mena-Hortelano R. et al. Podoplanin serum and urine concentration in transitional bladder cancer. Cancer Biomark. 2016. V. 16(3). P. 343-350. DOI: 10.3233/CBM-160572
  52. Zhao X., Pan Y., Ren W. et al. Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis. Cancer Sci. 2018 Feb. V. 109(2). P. 403–411. DOI: 10.1111/cas.13475
  53. Mello F.W., Kammer P.V., Silva C.A.B. et al. Prognostic and clinicopathological significance of podoplanin immunoexpression in oral and oropharyngeal squamous cell carcinoma: A systematic review. J. Oral Pathol. Med. 2021 Jan. V. 50(1). P. 1-9. DOI: 10.1111/jop.13041
  54. Petrova T.V., Mäkinen T., Mäkelä T.P. et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 2002 Sep 2. V. 21(17). P. 4593–4599. DOI: 10.1093/emboj/cdf470
  55. Hantusch B., Kalt R., Krieger S. et al. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol. Biol. 2007 Mar 7. V. 8. P. 20. DOI: 10.1186/1471-2199-8-20
  56. Durchdewald M., Guinea-Viniegra J., Haag D. et al. Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res. 2008 Sep 1. V. 68(17). P. 6877–6883. DOI: 10.1158/0008-5472.CAN-08-0299
  57. Kunita A., Kashima T.G., Ohazama A. et al. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am. J. Pathol. 2011 Aug. V. 179(2). P. 1041-9. DOI: 10.1016/j.ajpath.2011.04.027
  58. Shen Y., Chen C.S., Ichikawa H., Goldberg G.S. SRC induces podoplanin expression to promote cell migration. J. Biol. Chem. 2010 Mar 26. V. 285(13). P. 9649–9656. DOI: 10.1074/jbc.M109.047696
  59. Peterziel H., Müller J., Danner A. et al. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. Neuro Oncol. 2012 Apr. V. 14(4). P. 426–439. DOI: 10.1093/neuonc/nos055
  60. Mei Y., Zhang P., Zuo H. et al. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis. Oncogene. 2014 Jul 17.
    V. 33(29). P. 3839–3850. DOI: 10.1038/onc.2013.354
  61. Kunita A., Baeriswyl V., Meda C. et al. Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front. Am. J. Pathol. 2018 May. V. 188(5). P. 1276–1288. DOI: 10.1016/j.ajpath.2018.01.016
  62. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell. 2014 Mar 6. V. 14(3). P. 275–291. DOI: 10.1016/j.stem.2014.02.006
  63. Massagué J., Obenauf A.C. Metastatic colonization by circulating tumour cells. Nature. 2016 Jan 21. V. 529(7586). P. 298-306. DOI: 10.1038/nature17038
  64. Cojoc M., Mäbert K., Muders M.H., Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin. Cancer Biol. 2015 Apr. V. 31. P. 16-27. DOI: 10.1016/j.semcancer.2014.06.004
  65. Bortolomai I., Canevari S., Facetti I. et al. Tumor initiating cells: development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle. 2010 Mar 15. V. 9(6). P. 1194-1206. DOI: 10.4161/cc.9.6.11108
  66. Miyashita T., Higuchi Y., Kojima M. et al. Single cell time-lapse analysis reveals that podoplanin enhances cell survival and colony formation capacity of squamous cell carcinoma cells. Sci. Rep. 2017 Jan 6. V. 7. P. 39971. DOI: 10.1038/srep39971
  67. Shimada Y., Ishii G., Nagai K. et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci. 2009 Nov.
    V. 100(11). P. 2054-2059. DOI: 10.1111/j.1349-7006.2009.01295.x
  68. Nishijima N., Ishii G., Nagai K. et al. Cancer-initiating cell marker-positive cells generate metastatic tumors that recapitulate the histology of the primary tumors. Pathol. Int. 2013 Feb. V. 63(2). P. 94-101. DOI: 10.1111/pin.12039
  69. Islam F., Gopalan V., Wahab R. et al. Cancer stem cells in oesophageal squamous cell carcinoma: Identification, prognostic and treatment perspectives. Crit. Rev. Oncol. Hematol. 2015 Oct. V. 96(1). P. 9-19. DOI: 10.1016/j.critrevonc.2015.04.007
  70. Dahlrot R.H., Hermansen S.K., Hansen S., Kristensen B.W. What is the clinical value of cancer stem cell markers in gliomas? Int. J. Clin. Exp. Pathol. 2013. V. 6(3). P. 334-48.
  71. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer. 2006 May. V. 6(5). P. 392-401. DOI: 10.1038/nrc1877
  72. Calon A., Tauriello D.V., Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Semin. Cancer Biol. 2014 Apr. V. 25. P. 15–22. DOI: 10.1016/j.semcancer.2013.12.008
  73. Pula B., Witkiewicz W., Dziegiel P., Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. Int. J. Oncol. 2013 Jun. V. 42(6). P. 1849–1857. DOI: 10.3892/ijo.2013.1887
  74. Shindo K., Aishima S., Ohuchida K. et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol. Cancer. 2013 Dec 20. V. 12(1). P. 168. DOI: 10.1186/1476-4598-12-168
  75. Obulkasim H., Shi X., Wang J. et al. Podoplanin is an important stromal prognostic marker in perihilar cholangiocarcinoma. Oncol. Lett. 2018 Jan. V. 15(1). P. 137–146. DOI: 10.3892/ol.2017.7335
  76. Cui M., Dong H., Duan W. et al. The relationship between cancer associated fibroblasts biomarkers and prognosis of breast cancer: a systematic review and meta-analysis. PeerJ. 2024 Feb 23. V. 12. P. e16958. DOI: 10.7717/peerj.16958
  77. Irvine A.F., Waise S., Green E.W. et al. Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis. Sci. Rep. 2021 Feb 12. V. 11(1). P. 3727. DOI: 10.1038/s41598-021-81796-2
  78. Luanpitpong S., Wang L., Castranova V. et al. Induction of cancer-associated fibroblast-like cells by carbon nanotubes dictates its tumorigenicity. Sci. Rep. 2016 Dec 20. V. 6. P. 39558. DOI: 10.1038/srep39558
  79. Yoshida T., Ishii G., Goto K. et al. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin. Cancer Res. 2015 Feb 1. V. 21(3). P. 642–651. DOI: 10.1158/1078-0432.CCR-14-0846
  80. Gao H., Wong S.Q.R., Subel E. et al. Caspase-1-dependent pyroptosis converts αSMA+ CAFs into collagen-IIIhigh iCAFs to fuel chemoresistant cancer stem cells. Sci. Adv. 2025 Jun 13. V. 11(24). P. eadt8697. DOI: 10.1126/sciadv.adt8697
  81. Dallavalasa S., Beeraka N.M., Basavaraju C.G. et al. The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis – Current Status. Curr. Med. Chem. 2021. V. 28(39). P. 8203–8236. DOI: 10.2174/0929867328666210720143721
  82. Lafta H.A., AbdulHussein A.H., Al-Shalah S.A.J. et al. Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products. Curr. Top. Med. Chem. 2023. V. 23(12). P. 1104–1122. DOI: 10.2174/1568026623666230201145909
  83. Bieniasz-Krzywiec P., Martín-Pérez R., Ehling M. et al. Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. Cell Metab. 2019 Nov 5. V. 30(5). P. 917–936.e10. DOI: 10.1016/j.cmet.2019.07.015
  84. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4. V. 144(5). P. 646–674. DOI: 10.1016/j.cell.2011.02.013
  85. Masi I., Caprara V., Bagnato A., Rosanò L. Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation. Front. Cell Dev. Biol. 2020 Oct 15. V. 8. Article 584181. DOI: 10.3389/fcell.2020.584181
  86. Martín-Villar E., Borda-d'Agua B., Carrasco-Ramirez P. et al. Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability. Oncogene. 2015 Aug 20. V. 34(34). P. 4531-4544. DOI: 10.1038/onc.2014.388
  87. Te Boekhorst V., Preziosi L., Friedl P. Plasticity of Cell Migration In Vivo and In Silico. Annu. Rev. Cell Dev. Biol. 2016 Oct 6. V. 32. P. 491-526. DOI: 10.1146/annurev-cellbio-111315-125201
  88. Stuelten C.H., Parent C.A., Montell D.J. Cell motility in cancer invasion and metastasis: insights from simple model organisms. Nat. Rev. Cancer. 2018 May. V. 18(5). P. 296–312. DOI: 10.1038/nrc.2018.15
  89. Wicki A., Lehembre F., Wick N. et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006 Apr. V. 9(4). P. 261–272. DOI: 10.1016/j.ccr.2006.03.010
  90. Tozluoğlu M., Tournier A.L., Jenkins R.P. et al. Matrix geometry determines optimal cancer cell migration strategy and modulates response to interventions. Nat. Cell Biol. 2013 Jul. V. 15(7). P. 751–762. DOI: 10.1038/ncb2775
  91. Wyckoff J.B., Pinner S.E., Gschmeissner S. et al. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr. Biol. 2006 Aug 8. V. 16(15). P. 1515-23. DOI: 10.1016/j.cub.2006.05.065
  92. de Winde C.M., George S.L., Crosas-Molist E. et al. Podoplanin drives dedifferentiation and amoeboid invasion of melanoma. iScience. 2021 Aug 13. V. 24(9). P. 102976. DOI: 10.1016/j.isci.2021.102976
  93. Braun A., Anders H.J., Gudermann T., Mammadova-Bach E. Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. Front. Oncol. 2021 Jul 12. V. 11. P. 665534. DOI: 10.3389/fonc.2021.665534
  94. David C.J., Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 2018 Jul. V. 19(7). P. 419-435. DOI: 10.1038/s41580-018-0007-0
  95. Suzuki J., Aokage K., Neri S. et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021 Mar. V. 153. P. 1–10. DOI: 10.1016/j.lungcan.2020.12.020
  96. Nakamura H., Ichikawa T., Nakasone S. et al. Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions. Lung Cancer. 2018 Jan. V. 115. P. 56–63. DOI: 10.1016/j.lungcan.2017.11.013
  97. Pula B., Jethon A., Piotrowska A. et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology. 2011 Dec. V. 59(6). P. 1249–1260. DOI: 10.1111/j.1365-2559.2011.04060.x
  98. Shindo K., Aishima S., Ohuchida K. et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol. Cancer. 2013 Dec 20. V. 12(1). P. 168. DOI: 10.1186/1476-4598-12-168
  99. Sakai T., Aokage K., Neri S. et al. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. Lung Cancer. 2018 Dec. V. 126. P. 64–71. DOI: 10.1016/j.lungcan.2018.10.021
  100. Komohara Y., Jinushi M., Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014 Jan. V. 105(1). P. 1–8. DOI: 10.1111/cas.12314
  101. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. 2012 Mar 15. V. 12(4). P. 298–306. DOI: 10.1038/nrc3245
  102. Peters A., Burkett P.R., Sobel R.A. et al. Podoplanin negatively regulates CD4+ effector T cell responses. J. Clin. Invest. 2015 Jan.
    V. 125(1). P. 129–140. DOI: 10.1172/JCI74685
  103. Chihara N., Madi A., Kondo T. et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature. 2018 Jun. V. 558(7710). P. 454–459. DOI: 10.1038/s41586-018-0206-z
  104. Qin S., Xu L., Yi M. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer. 2019 Nov 6. V. 18(1).
    P. 155. DOI: 10.1186/s12943-019-1091-2
  105. Tatsumi K. The pathogenesis of cancer-associated thrombosis. Int. J. Hematol. 2024 May. V. 119(5). P. 495-504. DOI: 10.1007/s12185-024-03735-x
  106. Gi T., Kuwahara A., Yamashita A. et al. Histopathological Features of Cancer-Associated Venous Thromboembolism: Presence of Intrathrombus Cancer Cells and Prothrombotic Factors. Arterioscler. Thromb. Vasc. Biol. 2023 Jan. V. 43(1). P. 146–159. DOI: 10.1161/ATVBAHA.122.318463
  107. Diaz M., Jo J. Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients. Curr. Oncol. Rep. 2022 Apr. V. 24(4). P. 493–500. DOI: 10.1007/s11912-021-01178-9
  108. Riedl J., Preusser M., Nazari P.M. et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017 Mar 30. V. 129(13). P. 1831–1839. DOI: 10.1182/blood-2016-06-720714
  109. Kapteijn M.Y., Bakker N., Koekkoek J.A.F. et al. Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications. Thromb. Haemost. 2025 May. V. 125(5). P. 421-434. DOI: 10.1055/s-0044-1789592
  110. Thaler J., Ay C., Kaider A. et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol. 2014 Dec. V. 16(12). P. 1645–1651. DOI: 10.1093/neuonc/nou106
  111. Jo J., Diaz M., Horbinski C. et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. Neuro Oncol. 2023 Aug 3. V. 25(8). P. 1381–1394. DOI: 10.1093/neuonc/noad059
  112. Prouse T., Mohammad M.A., Ghosh S. et al. Pancreatic Cancer and Venous Thromboembolism. Int. J. Mol. Sci. 2024 May 23.
    V. 25(11). P. 5661. DOI: 10.3390/ijms25115661
  113. Hirayama K., Kono H., Nakata Y. et al. Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer. Surg. Today. 2018 Jan. V. 48(1). P. 110–118. DOI: 10.1007/s00595-017-1559-x
  114. Pelegrín-Mateo F.J., Zambrano C.B., Vázquez E.B. et al. Cancer genetic profile and risk of thrombosis. Eur. J. Intern. Med. 2025 Jun.
    V. 136. P. 19-26. DOI: 10.1016/j.ejim.2025.04.004
  115. Wang X., Liu B., Xu M. et al. Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis. Thromb. Res. 2021 Apr. V. 200. P. 72–80. DOI: 10.1016/j.thromres.2021.01.008
  116. Tawil N., Bassawon R., Meehan B. et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 2021. V. 5. P. 1682–1694. DOI: 10.1182/bloodadvances.2020002998
  117. Meng D., Luo M., Liu B. The Role of CLEC-2 and Its Ligands in Thromboinflammation. Front. Immunol. 2021 Jun 9. V. 12. Article 688643. DOI: 10.3389/fimmu.2021.688643
  118. Shirai T., Tsukiji N., Sasaki T. et al. Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model. J. Thromb. Haemost. 2023 Nov. V. 21(11). P. 3153-3165. DOI: 10.1016/j.jtha.2023.07.005
  119. Sasano T., Gonzalez-Delgado R., Muñoz N.M. et al. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J. Thromb. Haemost. 2022 Jan. V. 20(1). P. 104-114. DOI: 10.1111/jth.15544
  120. Pan Y. et al. Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets. Blood, The Journal of the American Society of Hematology. 2014. V. 124. P. 3656–3665.
  121. Carrasco-Ramírez P. et al. Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation. Oncotarget. 2016. V. 7. P. 16070.
  122. Mege D. et al. The origin and concentration of circulating microparticles differ according to cancer type and evolution: A prospective single‐center study. International journal of cancer. 2016. V. 138. P. 939–948.
  123. Kemi N., Eskuri M., Herva A. et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br. J. Cancer. 2018 Aug. V. 119(4). P. 435-439. DOI: 10.1038/s41416-018-0202-y
  124. Takiguchi K., Shoda K., Nakayama T. et al. Soluble podoplanin as a biomarker in diffuse type gastric cancer. Oncol. Rep. 2022 Mar.
    V. 47(3). P. 51. DOI: 10.3892/or.2022.8262
  125. Zhu X., Xu M., Zhao X. et al. The Detection of Plasma Soluble Podoplanin of Patients with Breast Cancer and Its Clinical Signification. Cancer Manag Res. 2020 Dec 23. V. 12. P. 13207-13214. DOI: 10.2147/CMAR.S281785
  126. Zhang Q., Peng K., Wang L. et al. Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer. Clin. Appl. Thromb. Hemost. 2023 Jan-Dec. V. 29. Article. 10760296231183432. DOI: 10.1177/10760296231183432
  127. Meliante P.G., Pizzolante S., Perna L. et al. Molecular Markers of Occult Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients. Front. Biosci. (Landmark Ed). 2025 Feb 20. V. 30(2). P. 25267. DOI: 10.31083/FBL25267
  128. Kato Y., Kaneko M.K., Kuno A. et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 2006 Nov 3. V. 349(4). P. 1301-1307. DOI: 10.1016/j.bbrc.2006.08.171
  129. Nakazawa Y., Takagi S., Sato S. et al. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci. 2011 Nov. V. 102(11). P. 2051–2057. DOI: 10.1111/j.1349-7006.2011.02058.x
  130. Takagi S., Sato S., Oh-hara T. et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One. 2013 Aug 21. V. 8(8). P. e73609. DOI: 10.1371/journal.pone.0073609
  131. Tsao L.C., Force J., Hartman Z.C. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Res. 2021 Sep 15. V. 81(18). P. 4641-4651. DOI: 10.1158/0008-5472.CAN-21-1109
  132. Kato Y., Kaneko M.K. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci. Rep. 2014 Aug 1. V. 4. P. 5924. DOI: 10.1038/srep05924
  133. Ukaji T., Takemoto A., Katayama R. et al. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis). Oncotarget. 2018 Sep 7. V. 9(70). P. 33322-33336. DOI: 10.18632/oncotarget.26055
  134. Ward P.L., Koeppen H., Hurteau T., Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 1989 Jul 1. V. 170(1). P. 217-32. DOI: 10.1084/jem.170.1.217
  135. Suzuki H., Ohishi T., Kaneko M.K., Kato Y. A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models. Cancers (Basel). 2023 Oct 20. V. 15(20). P. 5080. DOI: 10.3390/cancers15205080
  136. Tanaka T., Suzuki H., Ohishi T. et al. Antitumor Activities by a Humanized Cancer-Specific Anti-Podoplanin Monoclonal Antibody humPMab-117 Against Human Tumors. Cancer Sci. 2025 Aug. V. 116(8). P. 2232-2242. DOI: 10.1111/cas.70103
Date of receipt: 25.12.2025
Approved after review: 02.02.2026
Accepted for publication: 04.03.2026